Back

Cleavage of the vascular matrix attracts glioblastoma cells to infiltrate the brain parenchyma

Perryman, L.; Hoye, A.; Cox, T. R.; Baker, A.-M.; Strobech, J.; Leonte, L.; Singh, L. B.; Popov, S.; Lorentzen, L. G.; Reuten, R.; Skovgaard Poulsen, H.; Davies, M. J.; Jones, C.; Erler, J. T.

2024-08-06 cancer biology
10.1101/2024.08.02.606279 bioRxiv
Show abstract

BackgroundGlioblastoma is a highly aggressive brain cancer and, unlike many other cancers types, the median survival for patients after treatment (14.6 months) has barely improved in the last 20 years. Infiltrative growth into the surrounding brain parenchyma facilitates tumor recurrence and ultimately the death of the patient - novel therapies targeting this process are desperately needed. Lysyl oxidase inhibition has been shown to decrease invasive growth in a variety of solid tumours and is a potential therapy for glioblastoma patients. MethodsGenes highly expressed in the mesenchymal subtype of glioblastoma were analyzed in a data set from the Cancer Genome Atlas and tissue microarrays. Two patient-derived human glioblastoma stem cell lines were used to assess the involvement of lysyl oxidase (LOX). The effect of LOX on infiltration was examined in an organotypic brain slice assay and in an orthotopic mouse model. Chemotactic assays, protease and cleavage arrays were used to assess the underlying mechanism behind LOX-mediated infiltration. The orthotopic model was used to evaluate potential clinical utility of targeting LOX in glioblastoma. ResultsLOX is overexpressed in the mesenchymal glioblastoma subtype and strongly associated with poor patient survival. LOX expression upregulates MMP7 expression, which subsequently cleaves the vascular matrix resulting in increased chemotaxis of glioblastoma cells. ConclusionsWe have uncovered a novel mechanism of glioblastoma infiltration and suggest that targeting LOX represent an effective therapeutic approach blocking glioblastoma infiltration. Importance of the studyThe ability of glioblastoma cells to infiltrate the surrounding normal brain tissue facilitates their evasion of current therapies, leading to tumor recurrence and ultimately the death of the patient. To improve targeted therapies for glioblastoma patients we need to understand the molecular mechanisms of glioblastoma cell infiltration and how cells interact with the unique microenvironment of the brain. We have identified a novel mechanism whereby tumor-derived LOX mediates chemotaxis of glioblastoma cells to the laminin rich perivascular niche, enabling infiltrative growth. Inhibiting this infiltrative pathway is a potential anti-invasive therapy that is desperately needed for glioblastoma patients.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Neuro-Oncology Advances
24 papers in training set
Top 0.1%
33.0%
2
Neuro-Oncology
30 papers in training set
Top 0.1%
17.5%
50% of probability mass above
3
PLOS ONE
4510 papers in training set
Top 28%
6.4%
4
Cancers
200 papers in training set
Top 2%
3.7%
5
Neoplasia
22 papers in training set
Top 0.1%
2.6%
6
Acta Neuropathologica Communications
81 papers in training set
Top 0.3%
2.6%
7
Scientific Reports
3102 papers in training set
Top 45%
2.6%
8
International Journal of Cancer
42 papers in training set
Top 0.6%
1.8%
9
BMC Cancer
52 papers in training set
Top 1%
1.7%
10
Clinical Epigenetics
53 papers in training set
Top 0.6%
1.5%
11
npj Precision Oncology
48 papers in training set
Top 0.7%
1.5%
12
Frontiers in Oncology
95 papers in training set
Top 3%
1.2%
13
F1000Research
79 papers in training set
Top 3%
1.2%
14
Annals of Oncology
13 papers in training set
Top 0.7%
1.2%
15
Cancer Letters
32 papers in training set
Top 0.5%
0.9%
16
Clinical Cancer Research
58 papers in training set
Top 1%
0.9%
17
Frontiers in Genetics
197 papers in training set
Top 10%
0.7%
18
OncoImmunology
22 papers in training set
Top 0.4%
0.7%
19
Journal of the Neurological Sciences
17 papers in training set
Top 0.7%
0.7%
20
Nature Communications
4913 papers in training set
Top 63%
0.7%
21
Journal of Clinical Investigation
164 papers in training set
Top 6%
0.7%
22
Molecular Oncology
50 papers in training set
Top 1%
0.7%
23
Interface Focus
14 papers in training set
Top 0.3%
0.7%
24
Cancer Research
116 papers in training set
Top 4%
0.6%
25
Journal of Clinical Medicine
91 papers in training set
Top 7%
0.6%